Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SDEV vs APUS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

APUS Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 8–0 Matrix Metrics)

APUS Overall Winner 6-Pillar Tally: SDEV 1 – 2 APUS (3 Tie) Matrix Metrics: SDEV 0 – 8 APUS

As of Nov 16, 2026, Apimeds Pharmaceuticals US, Inc. (APUS) is the stronger overall head-to-head candidate over SDEV (SDEV) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). SDEV carries a Unified Composite Score of 45.8/100 (HOLD) at $0.71 (N/M Forward P/E, N/A operating margin), whereas APUS carries 48.5/100 (HOLD) at $2.05 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: SDEV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.6); meanwhile APUS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SDEV vs APUS
SDEV US Equity
SDEV
Institutional Equity
$0.71
-9.42% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.47β · 154% Vol
Unified Composite Score
45.8 / 100 HOLD
Tech 43.0 Fund 46.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.4%), weak momentum, RSI 41
RSI-14: 40.6 · SMA20: $0.94 · SMA50: $1.43
APUS NYSE American Head-to-Head Winner
Apimeds Pharmaceuticals US, Inc.
Pharmaceutical Preparations
$2.05
-7.91% 1D
Market Cap $3.4M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.97β · 67% Vol
Unified Composite Score
48.5 / 100 HOLD
Tech 43.0 Fund 49.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.9%), weak momentum, RSI 33
RSI-14: 33.4 · SMA20: $2.83 · SMA50: $3.43

6-Pillar Scorecard Institutional Category Breakdown (SDEV 1 – 2 APUS)

Columns: Metric · SDEV · APUS
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale APUS
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $3.4M
3. Profitability & Quality APUS
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A 0.0%
4. Balance Sheet & Cash Flow SDEV
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $14M Net Debt (0.14x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SDEV (0) vs APUS (8)
Institutional Metric SDEV APUS Criterion Row Edge
Market Capitalization
Scale
N/A $3.4M Larger Scale APUS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth APUS
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin APUS
Net Profit Margin
Profitability
N/A 0.0% Higher Margin APUS
Return on Equity (ROE)
Capital Efficiency
N/A 0.0% Higher ROE APUS
52-Week Range Position
Momentum
0% ($1–$10) 16% ($1–$10) Stronger Trend APUS
Beta / 30D Volatility
Risk Regime
1.47β · 154% Vol 2.97β · 67% Vol Lower Realized Risk APUS
Unified Institutional Score
Composite Signal
45.8 / 100 (HOLD) 48.5 / 100 (HOLD) Higher Composite APUS
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A ($14M Net Debt (0.14x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SDEV +29.38 pp
SDEV: -19.79% · APUS: -49.17%
3M Horizon SDEV +24.66 pp
SDEV: -24.0% · APUS: -48.66%
6M Horizon APUS +93.39 pp
SDEV: -55.57% · APUS: +37.82%
1Y Horizon APUS +19.04 pp
SDEV: -50.59% · APUS: -31.55%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SDEV vs APUS. Trailing 12-month operating profitability (SDEV N/A vs APUS 0.0%) and valuation multiples (SDEV N/M vs APUS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SDEV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
APUS ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E0.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SDEV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SDEV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
APUS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact APUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SDEV Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
APUS Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $3.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SDEV vs APUS Key Questions & Quantitative Answers

As of Nov 16, 2026, Apimeds Pharmaceuticals US, Inc. (APUS) is the stronger overall head-to-head candidate over SDEV (SDEV) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). SDEV carries a Unified Composite Score of 45.8/100 (HOLD) at $0.71 (N/M Forward P/E, N/A operating margin), whereas APUS carries 48.5/100 (HOLD) at $2.05 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: SDEV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.6); meanwhile APUS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

APUS leads the Growth & Scale pillar: SDEV posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with APUS at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SDEV generates N/A in USD-normalized revenue versus N/A for APUS. In operating R&D and SG&A reinvestment, SDEV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for APUS.

SDEV and APUS trade at balanced relative valuation multiples. SDEV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas APUS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SDEV (N/A ROE) versus APUS (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, SDEV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.47β · 154% Vol realized risk). By comparison, APUS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.97β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.